Sulfonylureas
PreclinicalSmall molecule
Eli LillySulfonylureas is one of 116 small molecule programs targeting Acute Pancreatitis. It is currently in Preclinical.
4
Indications
9
Total Trials
0
Active Trials
115
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Active Comparator
ModernaPreclinical
HS-20093
Jiangsu Hansoh Pharmaceutical Co., Ltd.Preclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
PEG-Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Cyclophosphamid
EEssen Biotech
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus5 trials
Type 2 Diabetes1 trial
Pancreatic Cancer1 trial
Incretin-based Drugs and Pancreatic Cancer
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02475499·886,172 enrolled
Heart Failure1 trial
Incretin-based Drugs and the Risk of Heart Failure
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02456428·1,499,650 enrolled
Acute Pancreatitis1 trial
Incretin-based Drugs and Acute Pancreatitis
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02476760·1,417,914 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sulfonylureas. EMBL-EBI & Wellcome Sanger Institute.
- [4]